EyePoint (EYPT) vs Lexeo Therapeutics (LXEO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Lexeo Therapeutics (LXEO) has outperformed EyePoint (EYPT) over the past year, losing 60.0% versus a loss of 75.1%. EyePoint is the larger company by market cap ($290.1 million vs $263.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EYPT | LXEO |
|---|---|---|
| Share price | $3.46 | $3.21 |
| Market cap | $290.09M | $263.50M |
| 1-day change | +4.22% | -3.02% |
| YTD return | -81.06% | -67.67% |
| 1-year return | -75.07% | -60.02% |
| 5-year return | -69.76% | — |
| EPS (TTM) | $-3.75 | $-1.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $19.11 | $10.99 |
| 52-week low | $3.05 | $2.98 |
| Distance from 52-week high | -81.89% | -70.79% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +648.84% | +532.40% |
| Average volume | 3.93M | 1.17M |
| Shares outstanding | 83.84M | 82.09M |
| Employees | 214 | 63 |
| Sector | Industrials | Health Care |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LXEO has outperformed EYPT by 15.0 percentage points over the past year.
- The two companies sit in different sectors: EyePoint in Industrials and Lexeo Therapeutics in Health Care.
About EyePoint
EYPT stock →EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases.
Industrials · Biotechnology: Laboratory Analytical Instruments · 214 employees
About Lexeo Therapeutics
LXEO stock →Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 63 employees
EYPT vs LXEO FAQ
Which is bigger, EyePoint or Lexeo Therapeutics?
EyePoint (EYPT) is larger, with a market capitalization of $290.09M compared with $263.50M for Lexeo Therapeutics (LXEO).
Which stock has performed better over the past year, EYPT or LXEO?
LXEO returned -60.02% over the past 12 months, compared with -75.07% for EYPT (price return, excluding dividends). Past performance does not predict future results.
Are EyePoint and Lexeo Therapeutics in the same industry?
No. EyePoint is in the Industrials sector, while Lexeo Therapeutics is in Health Care.